Protein therapeutics
Protein therapeutics are proteins used as experimental or approved therapies for disease states. They include "monoclonal antibodies (mAbs), peptide hormones, growth factors, plasma proteins, enzymes, and hemolytic factors"[1] While proteins can be more specific and flexible in their mechanism of action compared to small-molecule drugs, duration of action and drug delivery can be a challenge.[2][3][4]
References[edit]
- ^ Ramesh, Rajendran; Ravichandran, Ramakrishnan (2023). "Approved Protein Therapeutics and Their Biochemical Targets". Protein-based Therapeutics. Springer Nature. p. 199. doi:10.1007/978-981-19-8249-1_7. ISBN 978-981-19-8249-1.
- ^ Varanko, Anastasia; Saha, Soumen; Chilkoti, Ashutosh (2020). "Recent trends in protein and peptide-based biomaterials for advanced drug delivery". Advanced Drug Delivery Reviews. 156: 133–187. doi:10.1016/j.addr.2020.08.008. PMC 7456198. PMID 32871201.
- ^ Zaman, Rahela; Islam, Rowshan Ara; Ibnat, Nabilah; Othman, Iekhsan; Zaini, Anuar; Lee, Chooi Yeng; Chowdhury, Ezharul Hoque (May 2019). "Current strategies in extending half-lives of therapeutic proteins". Journal of Controlled Release. 301: 176–189. doi:10.1016/j.jconrel.2019.02.016.
- ^ Qin, Xiaofei; Yu, Changmin; Wei, Jing; Li, Lin; Zhang, Chengwu; Wu, Qiong; Liu, Jinhua; Yao, Shao Q.; Huang, Wei (November 2019). "Rational Design of Nanocarriers for Intracellular Protein Delivery". Advanced Materials. 31 (46). doi:10.1002/adma.201902791.
Further reading[edit]
- Sauna, Zuben E.; Kimchi-Sarfaty, Chava (2017). Protein Therapeutics. Springer. ISBN 978-3-319-41818-6.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |